reports
EDAP to Announce Second Quarter 2025 Financial Results on August 28, 2...
EDAP to Announce Second Quarter 2025 Financial Results on August 28, 2025 Company to host conference call and webcast on Thursday, August 28th at 8:30am EDT AUSTIN, Texas, August 7, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the second quarter ended June 30, 2025, before the markets open on Thursday, August 28th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and Fran...
EDAP Announces Transition from Foreign Private Issuer to U.S. Domestic...
EDAP Announces Transition from Foreign Private Issuer to U.S. Domestic Filer Status Transition to U.S. reporting status to take effect on January 1, 2026 AUSTIN, Texas, July 1, 2025 - EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, announced a change in its U.S. reporting status. EDAP TMS S.A. (the “Company”) currently qualifies as a foreign private issuer under applicable U.S. Securities and Exchange Commission (“SEC”) rules and regulations. Effective January 1, 2026, the Company will no longer qualify for foreign private issuer s...
EDAP to Present at the Jefferies Global Healthcare Conference
EDAP to Present at the Jefferies Global Healthcare Conference AUSTIN, Texas, May 27, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Global Healthcare Conference, which is being held June 3-5, 2025, in New York City. Presentation details: Date:Thursday, June 5th Time:4:20-4:50 PM ET Webcast: The live and archived webcast of the presentation can be accessed in the Investors section of th...
EDAP Reports First Quarter 2025 Financial Results
EDAP Reports First Quarter 2025 Financial Results Achieved a Record Number of Focal One® Robotic HIFU System Placements for a First Quarter Period Received CE Mark Designation for Focal One for the Treatment of Deep Infiltrating Endometriosis Positive Final Results of FARP Randomized Controlled Trial Presented at American Urology Association Annual Meeting (AUA 2025)Launched the New Focal One i Robotic HIFU System Performed World’s First Remote Transcontinental Focal One Robotic HIFU Procedure Successfully AUSTIN, Texas, May 15, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global lea...
EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025
EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025 Company to host conference call and webcast on Thursday, May 15th at 8:30am EDT LYON, France, May 1, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2025, before the markets open on Thursday, May 15th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, ...
EDAP Announces Positive Results from the FARP Randomized Controlled Tr...
EDAP Announces Positive Results from the FARP Randomized Controlled Trial Presented at the American Urological Association (AUA) Annual Meeting Final 3-year outcome of Focal Ablation versus Radical Prostatectomy (FARP) Randomized Controlled Trial (RCT) presented at 120th AUA Annual Meeting on Sunday, April 27, 2025. Study achieved its primary endpoint and demonstrated that the rate of treatment failure in the Focal Ablation (FA) group is non-inferior to that in the Radical Prostatectomy (RP) group at the final 36-month follow-up. AUSTIN, Texas, April 29, 2025 - EDAP TMS SA (Nasdaq: EDAP), ...
EDAP To Launch New Focal One® i Robotic HIFU system at the Upcoming 12...
EDAP To Launch New Focal One® i Robotic HIFU system at the Upcoming 120th American Urological Association (AUA) Annual Meeting Focal One i expands HIFUsion® patient-specific imaging compatibility to include PSMA PET, ExactVu™ Micro-Ultrasound, along with AI-driven and intelligent algorithms including Unfold AI™ and OnQ™ ProstateFocal One i extends HIFUsion capabilities to integrate Koelis® 3D biopsy maps and DynaCAD Urology datasetsFocal One i system will enable future capabilities including treatment streaming and recording, remote collaborative procedures and expanded clinical indications...
EDAP Announces Significant Presence of Focal One® at the Upcoming 120t...
EDAP Announces Significant Presence of Focal One® at the Upcoming 120th American Urological Association (AUA) Annual Meeting Activities to include expert-led demonstrations, semi-live Focal One procedures and hands-on simulations Final results of randomized clinical trial (FARP Study) comparing ultrasound-based focal ablation versus radical prostatectomy as a first-line treatment for prostate cancer Presentation on the first ever remote transatlantic Focal One Robotic HIFU procedure will be given by Ruben Olivares, MD, Urologic Surgeon at the Cleveland Clinic, at the AUA session of the Engi...
EDAP Reports Record HIFU Fourth Quarter and Full-Year 2024 Results
EDAP Reports Record HIFU Fourth Quarter and Full-Year 2024 Results Record full-year 2024 HIFU revenue of USD 25.7 million, an increase of 15.3% over full-year 2023Record Q4 2024 HIFU revenue of USD 9.3 million, an increase of 15.0% over Q4 2023U.S. Focal One HIFU procedures grew 51% on a year-over-year basis in 2024Focal One receives CE Mark for the treatment of deep infiltrating endometriosisRecent landmark HIFI study publication demonstrates positive outcomes with Focal One® Robotic HIFU versus surgery in the management of prostate cancerFirst patients treated in Phase I/II ...
EDAP to Announce Fourth Quarter and Full Year 2024 Financial Results o...
EDAP to Announce Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025 Company to host conference call and webcast on Thursday, March 27th at 8:30am EDT AUSTIN, Texas, March 6, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024, before the markets open on Thursday, March 27th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief...
EDAP Appoints Glen French to Board of Directors
EDAP Appoints Glen French to Board of Directors LYON, France, March 3, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Glen French to its Board of Directors. “We are pleased to welcome Glen to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS. “Glen is a highly accomplished executive with extensive business and clinical expertise in the development of innovative new medical devices and technology, and his presence on our Board of Director...
Cortechs.ai and EDAP Announce World’s First OnQ™ Prostate-Assisted Foc...
Cortechs.ai and EDAP Announce World’s First OnQ™ Prostate-Assisted Focal One® Robotic HIFU Procedure at UCSF Prostate Cancer Center First Focal One® procedure utilizing Cortechs.ai’s advanced MRI-imaging technology, OnQ Prostate, successfully performed at the University of California, San Francisco Prostate Cancer CenterOnQ Prostate’s Restriction Spectrum Imaging (RSI) technology improves lesion localization and targeting for urologists performing Focal One Robotic High Intensity Focused Ultrasound (HIFU) ablation Reflects EDAP’s continued commitment to innovation and further validates Foca...
EDAP Announces Preliminary Record Fourth Quarter Focal One® System Sal...
EDAP Announces Preliminary Record Fourth Quarter Focal One® System Sales and Record U.S. Procedures Company Reports Preliminary Worldwide Record Fourth Quarter Sales of 11 Focal One Systems Record U.S. Fourth Quarter Focal One System Sales Record Number of U.S. Focal One Procedures, with Year-Over-Year Growth of 30% AUSTIN, Texas, January 13, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced preliminary record Focal One System sales for the fourth quarter of calendar year 2024. The Company experienced ro...
EDAP Appoints Joshua H. Levine to Board of Directors
EDAP Appoints Joshua H. Levine to Board of Directors AUSTIN, Texas, January 10, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Joshua H. Levine to its Board of Directors. “We are pleased to welcome Josh Levine to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS. “Josh brings a wealth of executive experience and a track record of growing shareholder value by focusing on transformative, high growth business strategies within the medical technolog...
EDAP Announces First Pancreatic Cancer Patient Treated with Proprietar...
EDAP Announces First Pancreatic Cancer Patient Treated with Proprietary HIFU Technology AUSTIN, Texas, January 8, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first patient has been treated in a phase I/II PULS Trial sponsored by the Centre Léon Bérard, Lyon, France, evaluating proprietary High Intensity Focused Ultrasound (HIFU) technology for the treatment of pancreatic tumors. “The initiation of the PULS Trial represents a major milestone in efforts to develop a new and innovative approach for treating this devastating ...
Landmark HIFI Study Publication Demonstrates Positive Outcomes with Fo...
Landmark HIFI Study Publication Demonstrates Positive Outcomes with Focal One® Robotic HIFU Versus Surgery in the Management of Prostate Cancer HIFI Study is the largest (N = 3,328) prospective, comparative, multi-center clinical study ever conducted comparing prostate cancer treatmentsPositive study results are expected to drive further adoption of Focal One as a first line treatment option for the management of localized prostate cancer Study shows Focal One Robotic HIFU is non-inferior to surgery, meeting primary endpoint of non-inferiority for Salvage Treatment-free Survival (...
EDAP TMS S A : 1 director
A director at EDAP TMS S A sold 30,000 shares at 2.472USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
EDAP to Participate in the Piper Sandler 36th Annual Healthcare Confer...
EDAP to Participate in the Piper Sandler 36th Annual Healthcare Conference LYON, France, November 27, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced that Ryan Rhodes, Chief Executive Officer of EDAP TMS, is scheduled to participate in a fireside discussion and host 1x1 investor meetings at the upcoming Piper Sandler 36th Annual Healthcare Conference, which is taking place from December 3-5, 2024, in New York City. Presentation Details: Piper Sandler 36th Annual Healthcare Conference Format: Fireside Discussion Date: ...
EDAP Announces Scientific Presentation Highlighting Feasibility of Foc...
EDAP Announces Scientific Presentation Highlighting Feasibility of Focal One® to Perform Non-thermal Histotripsy Energy Delivery at the 187th Acoustical Society of America Meeting Early feasibility work demonstrates Focal One system’s ability to generate histotripsy lesions ex vivo LYON, France, November 22, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced a scientific presentation which demonstrated the technical feasibility of performing non-thermal histotripsy energy delivery and generating histotripsy lesions in biolo...
EDAP Announces Scientific Presentation at 2024 AAGL Global Congress Co...
EDAP Announces Scientific Presentation at 2024 AAGL Global Congress Comparing Focal One HIFU Versus Surgery for the Treatment of Deep Infiltrating Endometriosis Treatment with robotic HIFU showed reduction in moderate and severe post-operative complications and reduced hospital stay compared to surgery LYON, France, November 19, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced a moderated scientific presentation of clinical data comparing Focal One HIFU versus surgery for the treatment of deep infiltrating endometriosis ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.